X4 Pharmaceuticals, Inc financial data

Symbol
XFOR on Nasdaq, XFOWW on OTC
Industry
Biological Products, (No Diagnostic Substances)
Location
61 North Beacon Street, 4 Th Floor, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Arsanis, Inc. (to 3/13/2019)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 529 % +6.59%
Debt-to-equity 200 % +64%
Return On Equity 32.9 %
Return On Assets 11 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 168M shares +2.48%
Common Stock, Shares, Outstanding 168M shares +2.3%
Entity Public Float 318M USD +974%
Common Stock, Value, Issued 168K USD +2.44%
Weighted Average Number of Shares Outstanding, Basic 200M shares +18.8%
Weighted Average Number of Shares Outstanding, Diluted 201M shares +19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 563K USD
Revenue from Contract with Customer, Excluding Assessed Tax 700K USD
Cost of Revenue 268K USD
Research and Development Expense 75.1M USD +6.12%
General and Administrative Expense 48.8M USD +62.3%
Operating Income (Loss) -18.6M USD +81.6%
Nonoperating Income (Expense) 36.3M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 17.7M USD
Income Tax Expense (Benefit) 96K USD +380%
Net Income (Loss) Attributable to Parent 17.6M USD
Earnings Per Share, Basic 0.11 USD/shares
Earnings Per Share, Diluted 0.11 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 147M USD +7.91%
Cash, Cash Equivalents, and Short-term Investments 169M USD +19.5%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 175M USD +18.8%
Property, Plant and Equipment, Net 808K USD -6.91%
Operating Lease, Right-of-Use Asset 4.87M USD -24.5%
Goodwill 17.4M USD 0%
Other Assets, Noncurrent 1.79M USD +65.8%
Assets 211M USD +21.5%
Accounts Payable, Current 7.99M USD +56.3%
Employee-related Liabilities, Current 7.18M USD +26.4%
Accrued Liabilities, Current 19.7M USD +29.6%
Liabilities, Current 28.9M USD +29.9%
Operating Lease, Liability, Noncurrent 2.03M USD -35.1%
Other Liabilities, Noncurrent 979K USD -33.6%
Liabilities 116M USD +9.73%
Accumulated Other Comprehensive Income (Loss), Net of Tax -159K USD -33.6%
Retained Earnings (Accumulated Deficit) -439M USD +3.86%
Stockholders' Equity Attributable to Parent 94.5M USD +39.9%
Liabilities and Equity 211M USD +21.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120M USD -33.4%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -5.32M USD -59033%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 168M shares +2.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -39M USD -36.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 148M USD +7.67%
Deferred Tax Assets, Valuation Allowance 164M USD +23.2%
Deferred Tax Assets, Gross 165M USD +22.7%
Operating Lease, Liability 3.2M USD -25.1%
Lessee, Operating Lease, Liability, to be Paid 3.75M USD -28.7%
Property, Plant and Equipment, Gross 2.55M USD +8.43%
Operating Lease, Liability, Current 1.17M USD +2.09%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.33M USD -5.26%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +1.82%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 551K USD -44%
Lessee, Operating Lease, Liability, to be Paid, Year Three 280K USD -79%
Deferred Tax Assets, Operating Loss Carryforwards 123M USD +14.6%
Unrecognized Tax Benefits 200K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 47K USD -83.4%
Operating Lease, Payments 1.38M USD +1.17%
Current State and Local Tax Expense (Benefit) 0 USD
Current Federal Tax Expense (Benefit) 0 USD
Amortization of Intangible Assets 100K USD
Depreciation, Depletion and Amortization 62K USD -51.2%
Deferred Tax Assets, Net of Valuation Allowance 1.14M USD -24.3%
Share-based Payment Arrangement, Expense 9.07M USD +51%
Interest Expense 7.57M USD +71.3%